DataString Consulting Company Logo
DataString Consulting Company Logo
Zuranolone Market
Home»Recent Reports»Zuranolone Market

Zuranolone Market

Author: Debadatta Patel - Senior Consultant, Report ID - DS1802008, Published - January 2025

Segmented in Therapeutic Application (Depression, Postpartum Depression, Bipolar Disorder), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Prescription Type, End User and Regions - Global Industry Analysis, Size, Share, Trends, and Forecast 2024 – 2034

Share this report:

Global Zuranolone Market Outlook

Zuranolone is making waves in the field of health advancements by revolutionizing the way major depressive disorder (MDD) is treated. The market, for Zuranolone was estimated at $367.4 million in 2024. It is anticipated to increase to $694.7 million by 2030 with projections indicating a growth to around $1.2 billion by 2035. This expansion represents a compound annual growth rate (CAGR) of 11.2% over the forecast period. With its qualities that swiftly and effectively decrease depressive episodes. It marks a change, in modern psychiatric therapy.


Zuranolone is a man made hormone that works in a special way by affecting the receptors in the brain responsible for controlling emotions and mood swings. The current market buzz surrounding Zuranolone indicates an excitement over its upcoming regulatory clearance after proving its effectiveness in speeding up the recovery process, for individuals dealing with depressive symptoms during successful clinical tests.


Market Size Forecast & Key Insights

2019
$367M2024
2029
$1.1B2034

Absolute Growth Opportunity = $695M

The Zuranolone market is projected to grow from $367.4 million in 2024 to $1.06 billion in 2034. This represents a CAGR of 11.2%, reflecting rising demand across ZURANOLONE for Major Depressive Disorder (MDD) Treatment, ZURANOLONE for Generalized Anxiety Disorder (GAD) and ZURANOLONE for Postpartum Depression (PPD) Therapy.

The Zuranolone market is set to add $695 million between 2024 and 2034, with manufacturer targeting Retail Pharmacies & Online Pharmacies Distribution Channel projected to gain a larger market share.

With Rising mental health awareness, and Advances in neuroscience research, Zuranolone market to expand 189% between 2024 and 2034.

Opportunities in the Zuranolone Market

Potential Use Beyond Depression

The way Zuranolone affects the GABA A receptor in the brain suggests that it might be useful in treating conditions, like epilepsy or anxiety disorders. Fields that demand fresh perspectives and ideas.

Expanding Use in Treating Post-Partum Depression and Collaborations for Innovative Drug Delivery Methods

With its way of functioning and encouraging outcomes, in clinical trials so far Zuranolone has the potential to revolutionize the treatment of postpartum depression by exploring uncharted territory in this field and creating tailored therapies that may bring forth lucrative market prospects.

Zuranolones unique chemical composition could be enhanced through the utilization of cutting edge drug delivery techniques like nanoparticle based delivery systems. This advancement has the potential to foster partnerships with biotechnology firms specializing in drug delivery solutions enabling an expansion of market presence and presenting avenues, for growth opportunities.

Growth Opportunities in North America and Europe

Europe Outlook

The European market is poised for growth as awareness of mental health increases and the strong healthcare system backs up these medical advancements. While competition is tough ZURANOLONE could explore possibilities by forming partnerships, with local institutions and adhering to the EUs healthcare guidelines.

North America Outlook

The market for ZURANOLONE in North America is expected to be strong because of the rates of Major Depressive Disorder and ongoing investments in healthcare infrastructure. However the competition is tough due to alternatives and other direct rivals to ZURANOLONE. There are chances for growth through innovation and partnerships, with healthcare organizations.

North America Outlook

The market for ZURANOLONE in North America is expected to be strong because of the rates of Major Depressive Disorder and ongoing investments in healthcare infrastructure. However the competition is tough due to alternatives and other direct rivals to ZURANOLONE. There are chances for growth through innovation and partnerships, with healthcare organizations.

Europe Outlook

The European market is poised for growth as awareness of mental health increases and the strong healthcare system backs up these medical advancements. While competition is tough ZURANOLONE could explore possibilities by forming partnerships, with local institutions and adhering to the EUs healthcare guidelines.

Growth Opportunities in North America and Europe

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : United States, Germany, Japan, China, United Kingdom are expected to grow at 8.2% to 11.8% CAGR

2

Emerging Markets : India, Brazil, South Africa are expected to grow at 10.8% to 14.0% CAGR

Market Analysis Chart

Zuranolone is a medication focusing on treating various mental health issues like depression and sleep problems; this has attracted attention due to its potential benefits, in a market affected by the increasing global prevalence of such conditions.

Recent Developments and Technological Advancement

December 2024

Sage Therapeutics broadened its marketing efforts for Zuranolone to connect with an audience of potential patients.

October 2024

Approval for the use of Zuranolone has been granted in countries such as Canada and Australia. This expansion opens up markets and opportunities, for increased sales.

September 2024

Clinical studies have demonstrated that Zuranolone has proven effective in alleviating symptoms among individuals with depression. This has bolstered its position, within the market for health medications.

SAGE 217 or Zuranolone has been causing quite a stir in the field lately for its promising applications in treating various mental health conditions like major depressive disorder and postpartum depression . This groundbreaking development, by Sage Therapeutics introduces a perspective into the enduring mental health medication market.

Impact of Industry Transitions on the Zuranolone Market

As a core segment of the Pharmaceutical industry, the Zuranolone market develops in line with broader industry shifts. Over recent years, transitions such as Shift Towards Personalized Medicine and Increased Investment in Mental Health Research have redefined priorities across the Pharmaceutical sector, influencing how the Zuranolone market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

Shift Towards Personalized Medicine:

The Zuranolone market is going through a change as it moves towards personalized medicine due to the increased awareness of different patient reactions to treatments and the demand for more precise medication options tailored to individual needs, for better treatment efficiency and fewer side effects. By using markers and sophisticated algorithms to analyze patient information effectively. Healthcare professionals have the opportunity to offer personalized Zuranolone treatments tailored to each patients needs. This approach can bring added benefits to the market.

2

Increased Investment in Mental Health Research:

An important shift affecting the Zuranolone market is the rise in funding for research, on health.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions, have added another layer of complexity to the Pharmaceutical industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Pharmaceutical industry cascade into the Zuranolone market, setting the stage for its future growth trajectory.

Market Dynamics and Supply Chain

Driver: Rising Mental Health Awareness, and Surge in Healthcare Expenditure

The growing focus in society towards health has also brought attention to issues such as depression and anxiety in a significant way these days. This heightened awareness plays a role in driving the market expansion of Zuranolone given its primary use, for addressing depressive disorders.
With the increase in global spending for healthcare services there is also a growing trend towards allocating resources to the research and procurement of advanced pharmaceuticals, like Zuranolone. The readiness of governments and healthcare institutions to support high quality medications also serves as a factor propelling the market forward.
Recent advancements in the field of neuroscience are also revealing possibilities for medications such as Zuranolone that regulate neurotransmitter functions to achieve their medicinal benefits. The ongoing scientific developments are also promoting usage and subsequently driving expansion, in the market.

Restraint: Increasing Competition from Alternative Treatments

There is competition for Zuranolone as it competes with several other medications on the market for depression and anxiety treatment that are well established and FDA approved which patients and healthcare experts tend to choose initially over newer options like Zuranolone might restrict its market growth due to the increasing favorability towards psychotherapy and lifestyle changes as safer alternatives, among some providers and patients.

Challenge: Potential Side Effects and Safety Concerns

Like medications, in the pharmaceutical field doles out potential adverse reactions and safety worries that might hinder its market expansion prospects. The medication may induce feelings of dizziness and sleepiness among patients which could diminish its appeal to some individuals.

Supply Chain Landscape

Raw Material Suppliers

Sigma-Aldrich

Merck

Active Pharmaceutical Ingredient Production

Sage Therapeutics

Sun Pharma Advanced Research

Formulation & Tablet Production
Catalent Pharma Solutions / AbbVie
End-User Markets
Depression Treatment / Mood Disorder Treatment
Raw Material Suppliers

Sigma-Aldrich

Merck

Active Pharmaceutical Ingredient Production

Sage Therapeutics

Sun Pharma Advanced Research

Formulation & Tablet Production

Catalent Pharma Solutions

AbbVie

End-User Markets

Depression Treatment

Mood Disorder Treatment

Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeadingProvidersProvider Strategies
Depression Treatment
Healthcare & Pharmaceuticals
Sage Therapeutics, Biogen
Develop and commercialize innovative medicines to address significant unmet psychiatric disorders
Postpartum Depression Therapy
Healthcare & Pharmaceuticals
Sage Therapeutics, Biogen
Capitalizing on the unmet medical need there are few therapeutic solutions in the market
Insomnia Treatment
Healthcare & Pharmaceuticals
Sage Therapeutics
Develop innovative therapeutics grounded in neuroscience, to improve sleep quality and treat insomnia.

Elevate your strategic vision with in-depth analysis of key applications, leading market players, and their strategies. The report analyzes industry leaders' views and statements on the Zuranolone market's present and future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Zuranolone in ZURANOLONE for Major Depressive Disorder (MDD) Treatment, ZURANOLONE for Generalized Anxiety Disorder (GAD) and ZURANOLONE for Postpartum Depression (PPD) Therapy

ZURANOLONE for Major Depressive Disorder (MDD) Treatment

An oral neuroactive steroid called Zuranolone is mainly used to treat depressive disorder due to its fast acting and long lasting effects. Major companies such as Sage Therapeutics and Biogen have shown interest, in Zuranolone by collaborating on its worldwide advancement and market release.

ZURANOLONE for Generalized Anxiety Disorder (GAD)

Zuranolone also holds potential in treating anxiety disorder offering a different approach to therapy for individuals who do not only react positively to standard GAD medications. The rapid onset of effects and minimal side effects of Zuranolone elevate its value proposition, in the psychiatric medication sector.

ZURANOLONE for Postpartum Depression (PPD) Therapy

Zuranolone also plays a role in treating postpartum depression by standing out for its ability to alleviate symptoms within days instead of weeks like traditional antidepressants do. Providing quicker relief for new mothers in need of support during this challenging time period of their lives. The prominent companies in the market such, as Sage Therapeutics and Biogen are actively involved in researching and exploring the uses of Zuranolone in postpartum depression treatment.

Zuranolone vs. Substitutes:
Performance and Positioning Analysis

Unlike options available on the market zuranolone stands out as a medication that can be taken orally and acts as a modulator of the GABA A receptor without belonging to the benzodiazepine class. Its distinctive position in the field of medications suggests promising growth prospects thanks to its specialized approach, to treating depression.

Zuranolone
  • Fluoxetine /
  • Sertraline /
  • Citalopram
    Potential for rapid and significant reduction in depressive symptoms, Novel mechanism of action offering an alternative to existing treatments
    Risk of side effects
    Fast-acting relief, established safety profiles
    Potential for addiction, withdrawal symptoms

Zuranolone vs. Substitutes:
Performance and Positioning Analysis

Zuranolone

  • Potential for rapid and significant reduction in depressive symptoms, Novel mechanism of action offering an alternative to existing treatments
  • Risk of side effects

Fluoxetine / Sertraline / Citalopram

  • Fast-acting relief, established safety profiles
  • Potential for addiction, withdrawal symptoms

Unlike options available on the market zuranolone stands out as a medication that can be taken orally and acts as a modulator of the GABA A receptor without belonging to the benzodiazepine class. Its distinctive position in the field of medications suggests promising growth prospects thanks to its specialized approach, to treating depression.

Loading...

Research Methodology

This market research methodology defines the Zuranolone market scope, gathers reliable data, and validates findings using integrated primary and secondary research. Our systematic framework ensures precise market sizing, growth trend analysis, and competitive benchmarking.


Secondary Research Approach


We begin secondary research by defining the targeted market at Country and Regional levels. As part of the Pharmaceutical ecosystem, we analyze Zuranolone across Hospitals, Homecare, and Mental Health Centers Applications. Our team gathers data systematically from country level ministerial sources, industry associations & federations, trade databases, company annual & quarterly reports and other credential sources, enabling us to map global and regional market size, pricing trends, regulatory standards, and technology advancements.


Key Sources Referenced:


We benchmark competitors such as Sage Therapeutics, Pfizer Inc., and Johnson & Johnson by reviewing company financial statements, and regulatory filings. Our secondary insights identify key market drivers and constraints, forming the analytical foundation for primary research.


Primary Research Methods


We conduct structured interviews and surveys with industry stakeholders, including Raw Material Suppliers, Active Pharmaceutical Ingredient Production, and Formulation & Tablet Production. Our geographic coverage spans Americas (40%), Europe (30%), Asia-Pacific (25%) and Middle East & Africa (5%). Our online surveys generally achieve a response rate of above 65%, and telephone interviews yield 60%, resulting in above 92% confidence level with a ±7% margin of error.


Through targeted questionnaires and in-depth interviews, we capture purchase intent, adoption barriers, brand perception across Segment Type. We use interview guides to ensure consistency and anonymous survey options to mitigate response bias. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering & Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Company Market Share approaches to estimate and project market size with precision.


Top-down & Bottom-Up Process


In Top-down approach, we disaggregate global Pharmaceutical revenues to estimate the Zuranolone segment, using historical growth patterns to set baseline trends. Simultaneously, in Bottom-up approach, we aggregate Country-Level Demand Data to derive regional and global forecasts, which provide granular consumption insights. By reconciling both approaches, we ensure statistical precision and cross-validation accuracy.


We evaluate the supply chain, spanning Raw Material Suppliers (Sigma-Aldrich, Merck), Active Pharmaceutical Ingredient Production (Sage Therapeutics, Sun Pharma Advanced Research), and Formulation & Tablet Production. Our parallel substitute analysis examines Fluoxetine, Sertraline, and Citalopram, highlighting diversification opportunities and competitive risks.


Company Market Share & Benchmarking


We benchmark leading companies such as Sage Therapeutics, Pfizer Inc., and Johnson & Johnson, analyzing their capabilities in pricing, product features, technology adoption, and distribution reach. By assessing company-level revenues and product portfolios, we derive market share comparisons, clarifying competitive positioning and growth trajectories across the ecosystem.


Our integration of data triangulation, supply chain evaluation, and company benchmarking, supported by our proprietary Directional Superposition methodology enables us to deliver precise forecasts and actionable strategic insights into the Zuranolone market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Zuranolone Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 408 million
Revenue Forecast in 2034USD 1.06 billion
Growth RateCAGR of 11.2% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 2024367 million
Growth OpportunityUSD 695 million
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD million and Industry Statistics
Market Size 2024367 million USD
Market Size 2027505 million USD
Market Size 2029624 million USD
Market Size 2030694 million USD
Market Size 20341.06 billion USD
Market Size 20351.18 billion USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredTherapeutic Application, Distribution Channel, Prescription Type, End User
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledSage Therapeutics, Pfizer Inc., Johnson & Johnson, Merck & Co., GlaxoSmithKline plc, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca, Eli Lilly and Company, Allergan plc, Sanofi and Roche Holding AG
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • Assess and prioritize high-value markets with precision
  • Craft tailored entry and expansion roadmaps
  • De-risk investments through rigorous market intelligence
  • Architect dynamic pricing frameworks aligned to value creation
  • Unlock sustainable margin enhancement opportunities
  • Benchmark performance against global industry leaders
  • Strategically realign portfolios to future growth drivers
  • Accelerate commercialization of breakthrough offerings
  • Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Zuranolone Market Size, Opportunities & Strategic Insights, by Therapeutic Application

4.1Depression
4.2Postpartum Depression
4.3Bipolar Disorder
Chapter 5

Zuranolone Market Size, Opportunities & Strategic Insights, by Distribution Channel

5.1Hospital Pharmacies
5.2Retail Pharmacies
5.3Online Pharmacies
Chapter 6

Zuranolone Market Size, Opportunities & Strategic Insights, by Prescription Type

6.1On-prescription
6.2Over the counter
Chapter 7

Zuranolone Market Size, Opportunities & Strategic Insights, by End User

7.1Hospitals
7.2Homecare
7.3Mental Health Centers
Chapter 8

Zuranolone Market, by Region

8.1North America Zuranolone Market Size, Opportunities, Key Trends & Strategic Insights
8.1.1U.S.
8.1.2Canada
8.2Europe Zuranolone Market Size, Opportunities, Key Trends & Strategic Insights
8.2.1Germany
8.2.2France
8.2.3UK
8.2.4Italy
8.2.5The Netherlands
8.2.6Rest of EU
8.3Asia Pacific Zuranolone Market Size, Opportunities, Key Trends & Strategic Insights
8.3.1China
8.3.2Japan
8.3.3South Korea
8.3.4India
8.3.5Australia
8.3.6Thailand
8.3.7Rest of APAC
8.4Middle East & Africa Zuranolone Market Size, Opportunities, Key Trends & Strategic Insights
8.4.1Saudi Arabia
8.4.2United Arab Emirates
8.4.3South Africa
8.4.4Rest of MEA
8.5Latin America Zuranolone Market Size, Opportunities, Key Trends & Strategic Insights
8.5.1Brazil
8.5.2Mexico
8.5.3Rest of LA
8.6CIS Zuranolone Market Size, Opportunities, Key Trends & Strategic Insights
8.6.1Russia
8.6.2Rest of CIS
Chapter 9

Competitive Landscape

9.1Competitive Dashboard & Market Share Analysis
9.2Company Profiles (Overview, Financials, Developments, SWOT)
9.2.1Sage Therapeutics
9.2.2Pfizer Inc.
9.2.3Johnson & Johnson
9.2.4Merck & Co.
9.2.5GlaxoSmithKline plc
9.2.6Novartis AG
9.2.7Bristol-Myers Squibb Company
9.2.8AstraZeneca
9.2.9Eli Lilly and Company
9.2.10Allergan plc
9.2.11Sanofi
9.2.12Roche Holding AG